4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Autism by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 138 ongoing clinical trials involving Autism
Of the 138 trials,76 trials are in Phase II
Furthermore, 17 trials are in Phase I

Number of ongoing Clinical Trials (for drugs) involving Autism by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Autism, a Central Nervous System condition. The largest number of ongoing clinical trials for Autism is conducted in North America. Asia-Pacificand Europe are among some of the other prominent regions involved in Autism-related drug trials.

Massachusetts General Hospital: The leading ongoing Autism related clinical trial sponsor

Massachusetts General Hospitalis the top sponsor for Autism-related ongoing clinical trials.

Arizona State University, Tehran University of Medical Sciences, Duke University, and Stanford Universityare a few other notable clinical trial sponsors involved in Autism. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Autism

Aripiprazole (Abilify), Risperidone (Risperdal, Belivon),Sulpiride(Dolmatil, Equilid, Championyl, Dogmatil, DogmatilForte, Eglonil, Dogmatyl), and Risperidone(Risperidone) are among the key marketed drugs involving Autism.

Aripiprazole (Abilify) is an antipsychotic agent. It functions via 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Agonist; 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Agonist mechanism of action. It is formulated as tablets and solution for oral route of administration and injection solution for intramuscular route of administration. Aripiprazole is marketed for the treatment of Autism and several other indications includingBipolar Disorder (Manic Depression), Schizophrenia, Major Depressive Disorder, Tourette Syndrome. Aripiprazolewas first approved in 2002 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Otsuka Pharmaceutical Co Ltd, and Bristol-Myers Squibb Co.

Risperidone (Risperdal, Belivon), a psychotropic agent, belongs to the class of benzisoxazole derivatives. It functions via 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist mechanism of action. It is formulated astablets, film coated tablets, solution for oral administration and formulated as injections solution and powder for suspension for intramuscular administration. Risperidone is marketed for the treatment of Autism and several other indications includingAlzheimer's Disease, Dementia, Anxiety Disorders, Bipolar Disorder (Manic Depression), Depression, Schizophrenia, Mania, Dementia Associated with Alzheimer's Disease, and Psychosis. Risperidonewas first approved in 1992 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Johnson & Johnson.